세계의 생균치료제 및 미생물 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 지역별, 부문 예측(2025-2030년)

Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By Application (C. Difficile, Crohn´s Disease, IBS, Diabetes), By Region (North America, Europe, APAC, MEA), And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 생균치료제 및 미생물 CDMO 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 생균치료제 및 미생물 CDMO 시장 규모는 2030년까지 3억 9,749만 달러에 이르고, 2025-2030년까지 CAGR은 38.5%로 확대될 것으로 예측되고 있습니다. 시장은 최근 급속히 성장하고 있으며, 이러한 동향은 앞으로도 계속될 것으로 예측됩니다. 환자와 의료 제공자들 사이에서 염증성 장 질환, 암, 신경 질환을 포함한 다양한 질병의 치료에 있어서 생체생활 치료제 및 미생물 기반 치료제의 잠재적인 이점에 대한 이해가 높아지고 있습니다.

이러한 분야에 특화된 CDMO의 요구는 제약 기업 및 생명공학 기업에 의한 생균치료제 제품 및 미생물 기반 의약품에 대한 투자 확대로 이어지고 있으며, 이 동향은 향후 10년간 계속될 것으로 예측됩니다. LBP 및 미생물 기반 치료제 시장이 확대됨에 따라 기업은 이러한 제품을 개발하고 제조하는 데 필요한 기술을 갖춘 CDMO를 찾고 있습니다. 그 결과 세계 CDMO 시장이 성장하고 향후 수년간 크게 확대될 것으로 예측됩니다.

이러한 치료법의 개발은 복잡성을 높이고 있기 때문에 CDMO로의 아웃소싱은 제약 회사 및 생명 공학 기업에게 매력적인 선택이 되고 있습니다. 예를 들어, 임상 단계의 바이오 의약품 회사인 Exeliom Biosciences는 2023년 7월 EXL01의 여러 임상시험을 포함한 치료 파이프라인의 임상 개발을 진행하기 위해 2,630만 달러의 시리즈 A 자금 조달을 발표했습니다. EXL01은 감염과 암에 응용 가능한 새로운 면역 요법 약물입니다.

생균치료제 및 미생물 기반 치료제에는 용도에 맞는 시장 부문이 마련되어 있으며, 현재는 C.디피실 카테고리가 시장을 독점하고 있습니다. 2023년 10월, Ferring Pharmaceuticals는 미국 소화기 병학회(American College of Gastroenterology)의 2023년 연례 학술 집회에서 REBYOTA의 두 가지 발표를 실시했다고 보고했습니다. 미국 FDA가 승인한 최초의 단일 용량 미생물 기반 치료제입니다.

COVID-19의 팬데믹은 생균치료제 및 미생물 수탁 개발 제조 기관(CDMO) 시장에 큰 영향을 미쳤습니다. 관련 규제가 완화되고 건강 관리에 대한 주목도가 높아짐에 따라 LBP와 미생물 치료제 시장은 향후 몇년안에 회복될 것으로 예측됩니다.

생균치료제 제품 및 미생물 CDMO 시장 보고서 하이라이트

• C.디피실 감염증의 유병률 증가와 효과적인 치료에 대한 수요 증가에 의해 2024년에는 C.디피실이 최대의 매출 점유율을 차지했고, 생균치료제 제품 및 미생물 수탁 개발 및 제조 시장의 성장을 가속하고 있습니다.
• 많은 기업이 C.디피실 감염증을 치료하기 위한 제품의 개발과 제조에 주력하고 있어 시장의 확대를 견인하고 있습니다.
• 북미의 생균치료제 및 미생물 CDMO 시장은 2024년 세계 시장의 76.84%의 최대 점유율을 차지했습니다.
• 아시아태평양은 예측 기간 동안 CAGR 44.82%를 보일 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 생균치료제 및 미생물 CDMO 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조적인 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 기술 상황
• 가격 모델 분석
• 2024년 임상시험 건수 분석
• 업계 시장 분석 도구
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 생균치료제 및 미생물 CDMO 시장 : 용도별, 추정 및 동향 분석

• 부문 대시보드
• 생균치료제 및 미생물 CDMO 시장 : 용도 변동 분석
• 생균치료제 및 미생물 CDMO 시장 규모와 동향 분석 : 용도별, 2018-2030년
• C. 디피실
• 크론병
• IBS
• 당뇨병
• 기타

제5장 생균치료제 및 미생물 CDMO 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 노르웨이
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 경쟁의 분류
• Company Market Assessment Analysis, 2024
• 기업 프로파일
  • Arrant Bio
  • 4D Pharma
  • Cerbios
  • Biose Industrie
  • Assembly Biosciences, Inc.
  • Wacker Chemie AG
  • Quay Pharmaceuticals
  • NIZO
  • Lonza
  • Inpac Probiotics

>JHS

영문 목차

영문목차

Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends:

The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 397.49 million by 2030, expanding at a CAGR of 38.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.

Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology's 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights:

• C.difficle held the largest revenue share in 2024 owing to the increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the live biotherapeutic products and microbiome contract development and manufacturing market.
• Many companies focus on developing and manufacturing products for treating C.difficle infections, driving the market's expansion.
• North America live biotherapeutic products and microbiome CDMO market accounted for the largest share of 76.84% in 2024 of the global live biotherapeutic products and microbiome market.
• Asia Pacific is expected to grow at a CAGR of 44.82% during the forecast period. The market in Asia Pacific has witnessed significant growth and promising developments in recent years.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Information Analysis
  • 1.4.2. Market Formulation & Data Visualization
  • 1.4.3. Data Validation & Publishing
• 1.5. Model Details
  • 1.5.1. Commodity Flow Analysis (Model 1)
  • 1.5.2. Top Down Market Estimation (Model 2)
  • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
  • 1.5.4. Multivariate Analysis (Model 4)
• 1.6. List of Secondary Sources
• 1.7. List of Abbreviations
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Live Biotherapeutic Products And Microbiome CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High Potential of Live Biotherapeutic Products and Microbiome in Treating Chronic & Infectious Diseases
    • 3.2.1.2. Increase in Clinical Research on Live Biotherapeutic Products
    • 3.2.1.3. Increasing Demand for One-Stop-Shop CDMOs
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues in Outsourcing
    • 3.2.2.2. Availability of Substitutes
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Clinical Trial Volume Analysis, 2024
• 3.6. Industry Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Live Biotherapeutic Products and Microbiome CDMO Market Application Movement Analysis
• 4.3. Global Live Biotherapeutic Products and Microbiome CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. C. Difficle
  • 4.4.1. C. Difficle Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Crohn's disease
  • 4.5.1. Crohn's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. IBS
  • 4.6.1. IBS Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Diabetes
  • 4.7.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Transportation Services Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size & Forecasts Trend Analysis, 2018 to 2030 (USD Million)
• 5.4. North America
  • 5.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Competitive scenario
    • 5.4.2.3. Regulatory scenario
    • 5.4.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Competitive scenario
    • 5.4.3.3. Regulatory scenario
    • 5.4.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Competitive scenario
    • 5.4.4.3. Regulatory scenario
    • 5.4.4.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Competitive scenario
    • 5.5.2.3. Regulatory scenario
    • 5.5.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Competitive scenario
    • 5.5.3.3. Regulatory scenario
    • 5.5.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Competitive scenario
    • 5.5.4.3. Regulatory scenario
    • 5.5.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Competitive scenario
    • 5.5.5.3. Regulatory scenario
    • 5.5.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Competitive scenario
    • 5.5.6.3. Regulatory scenario
    • 5.5.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Competitive scenario
    • 5.5.7.3. Regulatory scenario
    • 5.5.7.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Norway
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Competitive scenario
    • 5.5.8.3. Regulatory scenario
    • 5.5.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Sweden
    • 5.5.9.1. Key country dynamics
    • 5.5.9.2. Competitive scenario
    • 5.5.9.3. Regulatory scenario
    • 5.5.9.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Competitive scenario
    • 5.6.2.3. Regulatory scenario
    • 5.6.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Competitive scenario
    • 5.6.3.3. Regulatory scenario
    • 5.6.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Competitive scenario
    • 5.6.4.3. Regulatory scenario
    • 5.6.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Australia
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Competitive scenario
    • 5.6.5.3. Regulatory scenario
    • 5.6.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Competitive scenario
    • 5.6.6.3. Regulatory scenario
    • 5.6.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key country dynamics
    • 5.6.7.2. Competitive scenario
    • 5.6.7.3. Regulatory scenario
    • 5.6.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Competitive scenario
    • 5.7.2.3. Regulatory scenario
    • 5.7.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Competitive scenario
    • 5.7.3.3. Regulatory scenario
    • 5.7.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Competitive scenario
    • 5.8.2.3. Regulatory scenario
    • 5.8.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Competitive scenario
    • 5.8.3.3. Regulatory scenario
    • 5.8.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Competitive scenario
    • 5.8.4.3. Regulatory scenario
    • 5.8.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key country dynamics
    • 5.8.5.2. Competitive scenario
    • 5.8.5.3. Regulatory scenario
    • 5.8.5.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Competition Categorization
• 6.2. Company Market Assessment Analysis, 2024
• 6.3. Company Profiles
  • 6.3.1. Arrant Bio
    • 6.3.1.1. Company overview
    • 6.3.1.2. Financial performance
    • 6.3.1.3. Service benchmarking
    • 6.3.1.4. Strategic initiatives
  • 6.3.2. 4D Pharma
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Service benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. Cerbios
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Service benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. Biose Industrie
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Service benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Assembly Biosciences, Inc.
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Service benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Wacker Chemie AG
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Service benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Quay Pharmaceuticals
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Service benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. NIZO
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Service benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Lonza
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Service benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Inpac Probiotics
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Service benchmarking
    • 6.3.10.4. Strategic initiatives

관련자료